MX2022008973A - Metodos de desglicosilacion para electroforesis de proteinas glicosiladas. - Google Patents

Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.

Info

Publication number
MX2022008973A
MX2022008973A MX2022008973A MX2022008973A MX2022008973A MX 2022008973 A MX2022008973 A MX 2022008973A MX 2022008973 A MX2022008973 A MX 2022008973A MX 2022008973 A MX2022008973 A MX 2022008973A MX 2022008973 A MX2022008973 A MX 2022008973A
Authority
MX
Mexico
Prior art keywords
electrophoresis
glycosylated proteins
methods
deglycosylation methods
deglycosylation
Prior art date
Application number
MX2022008973A
Other languages
English (en)
Inventor
Ying Wang
Hunter Chen
Yiming Zhao
Timothy Riehlman
Shao- Chun WANG
Gabriel Carreau
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022008973A publication Critical patent/MX2022008973A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
    • G01N27/04—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
    • G01N27/041—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44756—Apparatus specially adapted therefor
    • G01N27/44791—Microapparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/24—Extraction; Separation; Purification by electrochemical means
    • C07K1/26—Electrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Electrochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La descripción se refiere a métodos para analizar una proteína de interés modificada postraduccionalmente mediante el uso de electroforesis, los métodos comprenden desglicosilar la proteína de interés después del etiquetado.
MX2022008973A 2020-01-21 2021-01-20 Metodos de desglicosilacion para electroforesis de proteinas glicosiladas. MX2022008973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062963646P 2020-01-21 2020-01-21
PCT/US2021/014111 WO2021150558A1 (en) 2020-01-21 2021-01-20 Deglycosylation methods for electrophoresis of glycosylated proteins

Publications (1)

Publication Number Publication Date
MX2022008973A true MX2022008973A (es) 2022-08-11

Family

ID=74798013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008973A MX2022008973A (es) 2020-01-21 2021-01-20 Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.

Country Status (11)

Country Link
US (2) US11835527B2 (es)
EP (2) EP4354145A3 (es)
JP (2) JP7342279B2 (es)
KR (2) KR102544013B1 (es)
CN (1) CN115398236B (es)
AU (2) AU2021209866B2 (es)
BR (2) BR112022014212B1 (es)
CA (1) CA3165060C (es)
IL (2) IL294765B2 (es)
MX (1) MX2022008973A (es)
WO (1) WO2021150558A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021209866B2 (en) 2020-01-21 2023-07-06 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859581A (en) * 1986-03-10 1989-08-22 Board Of Regents, The University Of Texas System Endoglycosidase assay
DK0417563T3 (da) 1989-09-12 2000-11-06 Hoffmann La Roche TNF-bindende proteiner
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
TW574597B (en) 2002-03-08 2004-02-01 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
DE10258150A1 (de) 2002-12-10 2004-07-08 Dyomics Gmbh Hydrophile Marker auf der Basis von Benzopyrylo-Polymethinen
JP4568551B2 (ja) 2004-07-28 2010-10-27 一晃 掛樋 糖たん白質糖鎖の分析方法及び非標識糖鎖の製造方法
EP2374818B1 (en) 2006-06-02 2012-12-19 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2486205C2 (ru) 2007-07-31 2013-06-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к cd20 человека и способ их использования
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2010122460A1 (en) 2009-04-20 2010-10-28 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
SG189220A1 (en) 2010-10-06 2013-05-31 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8709830B2 (en) 2011-03-18 2014-04-29 Biotium, Inc. Fluorescent dyes, fluorescent dye kits, and methods of preparing labeled molecules
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
RS56796B1 (sr) 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
WO2013112438A1 (en) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
WO2013192530A2 (en) 2012-06-21 2013-12-27 Children's Medical Center Corporation Methods and reagents for glycoproteomics
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
EA028244B1 (ru) 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9664608B2 (en) 2013-08-20 2017-05-30 Advanced Polymer Monitoring Technologies, Inc. Characterization of polymer and colloid solutions
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PL3126388T3 (pl) 2014-03-11 2019-10-31 Regeneron Pharma Przeciwciała anty-egfrviii i ich zastosowania
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
WO2015184325A2 (en) * 2014-05-30 2015-12-03 New England Biolabs, Inc. Deglycosylation reagents and methods
CN105277398A (zh) 2014-06-12 2016-01-27 中国科学院大连化学物理研究所 一种特殊糖肽富集和鉴定的方法
US20160068884A1 (en) 2014-09-09 2016-03-10 Bio-Techne Corporation Methods for determining presence or absence of glycan epitopes on glycoproteins
MX2017003535A (es) 2014-09-16 2017-10-27 Regeneron Pharma Anticuerpos anti-glucagon y sus usos.
JP7055634B2 (ja) 2014-10-30 2022-04-18 ウオーターズ・テクノロジーズ・コーポレイシヨン 標識化グリコシルアミンの迅速調製およびそれを生成するグリコシル化生体分子の分析方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
WO2016174564A1 (en) 2015-04-30 2016-11-03 Dh Technologies Development Pte. Ltd. Identification of glycosylation forms
US20160348139A1 (en) * 2015-05-29 2016-12-01 Michael J. KIMZEY Use of bile detergents to denature glycoproteins prior to enzymatic digestion
EP3500842B1 (en) * 2016-08-17 2024-04-10 Agilent Technologies, Inc. Use of mild electrophiles to reduce artifacts in analyzing glycans released from glycoproteins or glycopeptides
WO2018067449A1 (en) 2016-10-05 2018-04-12 Bio-Techne Corporation Methods and kits for assaying endoglycosidase activity
AU2017360807A1 (en) * 2016-11-18 2019-06-06 Biocon Limited Rapid and efficient de-glycosylation of glycoproteins
CN111868085A (zh) * 2018-03-19 2020-10-30 瑞泽恩制药公司 微芯片毛细管电泳测定法及试剂
AU2021209866B2 (en) 2020-01-21 2023-07-06 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins

Also Published As

Publication number Publication date
BR112022014212B1 (pt) 2024-01-23
BR122023021668A2 (pt) 2024-01-09
KR20230088853A (ko) 2023-06-20
JP2023166478A (ja) 2023-11-21
CA3165060A1 (en) 2021-07-29
EP4085253A1 (en) 2022-11-09
US20240053353A1 (en) 2024-02-15
EP4085253B1 (en) 2024-03-13
US11835527B2 (en) 2023-12-05
AU2021209866B2 (en) 2023-07-06
CN115398236A (zh) 2022-11-25
WO2021150558A1 (en) 2021-07-29
EP4354145A2 (en) 2024-04-17
IL294765A (en) 2022-09-01
US20210223256A1 (en) 2021-07-22
EP4354145A3 (en) 2024-07-03
AU2021209866A1 (en) 2022-08-18
KR20220121892A (ko) 2022-09-01
AU2023226678A1 (en) 2023-09-28
IL303596A (en) 2023-08-01
KR102544013B1 (ko) 2023-06-19
CA3165060C (en) 2023-06-20
IL294765B2 (en) 2023-12-01
JP2023506090A (ja) 2023-02-14
JP7342279B2 (ja) 2023-09-11
CN115398236B (zh) 2024-06-11
IL294765B1 (en) 2023-08-01
BR112022014212A2 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
MX2021005757A (es) Metodos y composiciones para la secuenciacion de proteinas.
AU2017259794A1 (en) Macromolecule analysis employing nucleic acid encoding
CR20170351A (es) Proteínas de unión a icos
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
BR112022003241A2 (pt) Fontes de proteína não animal com propriedades fucionais
MX2018009339A (es) Métodos para la identificación y análisis de secuencias de aminoácidos de las proteínas.
MX2020000288A (es) Cromatografia.
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
BRPI0413644A (pt) métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
SE0201655D0 (sv) A method of electrophoresis
GB202203844D0 (en) Methods for cell-free protein expression
MX2022008973A (es) Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
ZA202102547B (en) Methods for characterizing disulfide bonds
AR114569A1 (es) Glucuronidación como una modificación postraduccional ácida en anticuerpos monoclonales
MX2018013372A (es) Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos.
ATE479770T1 (de) Mikrowellengestützte deglycosylierung von proteinen zur molekulargewichtsbestimmung durch massenspektrometrie
WO2009145532A3 (ko) 비젤방식의 2차원 단백질분리용 다중채널장치
MX2021014336A (es) Caracterizacion de variantes de carga especificas del dominio de anticuerpos.
ZA202308985B (en) Constructs and methods for increased expression of polypeptides
MX2021007518A (es) Metodo de extraccion de proteina a partir de material vegetal de cannabis.
GB2522131A (en) Isotopic labelling of proteins
MX2021001915A (es) Metodo y sistema de cromatografia para determinar la cantidad y pureza de una proteina multimerica.
MX2020011631A (es) Ensayo de acetaminofeno.
EA202091713A1 (ru) Биологический синтез аминокислотных цепей для получения пептидов и белков
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs